ASH 2021 | Debulking strategies in CLL before venetoclax therapy
Ian Flinn
• 9 Dec 2021
Patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) receiving venetoclax may experience tumor lysis syndrome. Ian Flinn, MD, PhD, Tennessee Oncology, Nashville, TN, discusses data from a Phase IIIb trial (NCT03406156) of obinutuzumab monotherapy or bendamustine in treatment naïve patients with CLL/SLL as a debulking strategy. A vast majority of patients achieved low tumor burden after debulking, and achieved an undetectable minimal residual disease status. A successful debulking regimen will increase accessibility to venetoclax for more patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
